期刊文献+

6b,11b-二羟基-9,9-二甲基-7-对甲氧基苯基-8,9,10,11b-四氢化6bH-苊并[1,2-b]吲哚-11(7H)-酮的合成和晶体结构

Synthesis and crystal structure of 6b,11b-dihydroxy-7-aryl-8,9,10,11b-tetrahydroacenaphtho[1,2-b]indol-11(7H)-one
原文传递
导出
摘要 利用L-脯氨酸催化的烯胺酮(1)与苊醌(2)的加成、环化串联反应,合成得到了6b,11b-二羟基-9,9-二甲基-7-对甲氧基苯基-8,9,10,11b-四氢化6bH-苊并[1,2-b]吲哚-11(7 H)-酮(3).标题化合物的结构通过单晶X射线衍射法确定,晶体属于单斜晶系,空间群C2/c,相对分子质量Mr=427.48,晶胞参数a=3.1870(6)nm,b=0.97422(19)nm,c=1.3648(3)nm,V=4.2344(15)nm3,Z=8,晶胞密度Dc=1.341g·cm-3,吸收系数μ=0.090mm-1,单胞中电子的数目F(000)=1808.晶体结构用直接法解出,经全矩阵最小二乘法对原子参数进行修正,最终的偏离因子为R=0.0957,wR=0.2724.在晶体结构中2个羟基处于顺式,通过分子间氢键形成二聚体. The title compound 6 b,11 b-dihydroxy-7-aryl-8,9,10,11 b-tetrahydroacenaphtho[1,2-b]indol-11(7 H)-one derivatives(3)has been synthesized by the tandem reaction of enaminones and acenaphthequinone catalyzed by L-proline.The structure of compound3 was determined by single crystal X-ray diffraction analysis.The crystal is monoclinic,space group C2/c,with Mr=427.48,a=3.1870(6)nm,b=0.97422(19)nm,c=1.3648(3)nm,V=4.2344(15)nm3,Z=8,Dc=1.341 g·cm-3,μ=0.090 mm-1,F(000)=1808.The structure was solved by direct methods and refined by full-matrix least squares method to the final R=0.0957,wR=0.2724.X-ray analysis reveals that two hydroxy groups are in cis form.The dimer was formed by intermolecular hydrogen bonds in the molecule.
作者 杨芳 林伟 史达清 YANG Fang;LIN Wei;SHI Da-qing(Suzhou Institute of Construction and Communication,Suzhou 215104,China;School of Chemical and Environmental Engineering,Jiangsu University of Technology,Changzhou 213001,China;College of Chemistry,Chemical Engineering and Materials Science,Soochow University,Suzhou 215123,China)
出处 《分子科学学报》 CAS 北大核心 2019年第6期497-502,I0003,共7页 Journal of Molecular Science
基金 江苏省高校自然科学重大资助项目(15KJA150006)
关键词 四氢化苊并[1 2-d]吲哚-11(7H)-酮 合成 晶体结构 tetrahydroacenaphtho[1,2-b]indol-11(7H)-one synthesis crystal structure
  • 相关文献

参考文献3

二级参考文献83

  • 1KARADE, Nandkishor. N.,GAMPAWAR, Sumit V.,SHINDE, Sandeep. V.,JADHAV, Wamanrao. N..L-Proline Catalyzed Solvent-Free Knoevenagel Condensation for the Synthesis of 3-Substituted Coumarins[J].Chinese Journal of Chemistry,2007,25(11):1686-1689. 被引量:6
  • 2WANG C G, WU C Y,ZHU J Q, et al.[J].J Med Chem,2011,54(7):2331-2340.
  • 3JUNG H S, KWON P S, LEE J W, et al.[J].J Am Chem Soc,2009,131(5):2008-2012.
  • 4CHEN J J, LI K T, YANG D Y, et al.[J].Org Lett,2011, 13(7): 1658-1661.
  • 5ZHAO Y R, ZHENG Q, DAKIN K, et al.[J].J Am Chem Soc,2004,126(14):4653-4663.
  • 6CARDOSO C R, BRITO F C F, SILVA K C M, et al.[J].Bioorg Med Chem Lett,2002,12:9212-9218.
  • 7BONDAVALLI F, BOTTA M, BRUNO O, et al.[J].J Med Chem, 2002,45(22):4875-4887.
  • 8ALLEN D G, COE D M, COOK C M, et al.Preparation of pyrazolo[3,4-b]pyridine derivativesfor use in pharmaceutical compositions as phosphodiesterase inhibitors: world, 2004056823Al [P]. 2004-07-08.
  • 9HOEHN H.Imidazolylethoxy derivatives of pyrazolo[3,4-b]pyridine-5-methanols:USA,4159380A[P]. I979-06-26.
  • 10HELGA F,UWE H.Preparation of 2-hydrazino-4, 5, 6, 7-tetrahydropyrazolo[1,5-a]pyridine from hydrazine and 1,1,7-trichloro- 1-hepten-3-one: Germany, 19613753A 1 [P]. 1997-10-02.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部